Taisho’s in-house insomnia therapeutic candidate vornorexant offers a potential advantage of a shorter half-life compared to its competitors, which can contribute to patients’ QOL.

After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape. 

After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape. Generics Bulletin looks at the latest trends.

As it completed its takeover of Xellia’s finished dosage form business and related assets, Hikma set out how it expects its injectables business to benefit from the acquisition.